Ketamine and Spravato
Unlocking New Hope for Treatment-Resistant Mood Disorders
Transformative Ketamine Treatment:
Experience the benefits of ketamine treatment for depression at our Washington, DC location. Our ketamine treatments typically last around an hour (plan for up to 2 hours) and are administered in a safe and supportive environment. To ensure your safety, we advise that a friend or family member accompany you to the session. While some experience dissociation due to the anesthetic effects, it is usually non-threatening and often pleasant. We monitor your experience closely, and if needed, can stop the infusion or provide medication to alleviate any discomfort.
Your Journey to Healing:
Exploring Intranasal Esketamine (SPRAVATO™):
In addition to intravenous ketamine, we also offer intranasal esketamine, known as SPRAVATO™. This method involves a 2-hour procedure directed by our skilled physicians and nursing staff. The effects are similar to intravenous ketamine, but the delivery method differs (nasal). If you’re curious about insurance coverage for intranasal esketamine, please contact us for more information.
At Washington Interventional Psychiatry, we believe in forging new paths to healing. Contact us today to explore the possibilities and take the first step towards transformative relief.
How Ketamine Treats Depression
Ketamine for Depression
Cost and Coverage at Washington Interventional Psychiatry
We understand that navigating the financial aspect of mental health treatment is important. Here’s what you need to know about the cost and coverage of our services:
Ketamine Infusions for Depression:
Unfortunately, insurance coverage for our ketamine treatment for depression is limited. While we don’t participate in insurance plans or bill them on your behalf, we will provide you with the necessary forms to submit to your insurance company for potential reimbursement.
For your convenience, the initial consultation with our psychiatrists is complimentary. Each ketamine infusion is priced at $500 per session. The initial protocol comprises six infusions over a two-week period, totaling $3000 for the induction phase. Subsequent infusions are determined based on your response to the medication, typically occurring every four weeks.
Intranasal Esketamine (SPRAVATO™):
We are proud to offer FDA-approved intranasal esketamine (SPRAVATO™) for treatment-resistant depression (TRD) at Washington Interventional Psychiatry. As with ketamine infusions, our psychiatrists will evaluate your eligibility for this treatment option and provide prescriptions accordingly. The consultation with our psychiatrists is complimentary.
While we strive to facilitate insurance approval for esketamine, co-pays can vary. Please contact us to determine the estimated out-of-pocket cost. The administration and monitoring of esketamine for two hours are priced at $300 per session. If your current psychiatrist can prescribe the medication, we can administer it at our facility, potentially waiving the initial consultation.
Referrals and Urgent Cases:
For physicians or nurses calling from an emergency room seeking to refer a patient for our ketamine treatments, we strive to accommodate your patient within 24 hours. If you’re a physician, NP, or psychiatrist interested in making a referral, please visit our referral tab or reach out to us. Alternatively, you can schedule a 15-minute appointment with one of our psychiatrists to discuss your patient’s case.
Safety Measures and Transportation:
Patient safety is paramount. Due to the possibility of delayed effects, patients will be monitored by healthcare professionals for at least two hours following each treatment. Blood pressure will be closely observed and managed if necessary.
Please note that SPRAVATO™ and all other routes of ketamine may impair driving ability, requiring transportation from our treatment center. We currently require patients to be driven home by a friend or family member.
For any further details or clarifications, please don’t hesitate to reach out. Your well-being is our priority at Washington Interventional Psychiatry.
Can you tell me more about Ketamine?
Intravenous Ketamine is not, however nasal esketamine (SPRAVATO™) is FDA approved. They are the same drug (ketamine), absorption rates and the delivery process (intravenous vs intranasal) differs.
https://open.spotify.com/playlist/0dzvZDZNckuXLizbkP5nUC?si=1ytDbu7 NS5W3d_gJfhxR5w ■ https://open.spotify.com/playlist/6EBtnrgLRXUI0mrvgyJVLc?si=25e07c7ff e5c4b42 ■ https://open.spotify.com/playlist/0dzvZDZNckuXLizbkP5nUC?si=ae44d08 da9a44cd2 ■ https://open.spotify.com/playlist/4ps9SddRPpiT5Sl0Mz6y4h?si=d27254f8 ad7e4963 ■ https://open.spotify.com/playlist/4TyxddhXPv3Xjw5MNQq2wy?si=1802ea 7f152e471c